These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9021256)

  • 41. Glutamate, excitotoxicity and amyotrophic lateral sclerosis.
    Shaw PJ; Ince PG
    J Neurol; 1997 May; 244 Suppl 2():S3-14. PubMed ID: 9178165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex.
    Bristol LA; Rothstein JD
    Ann Neurol; 1996 May; 39(5):676-9. PubMed ID: 8619555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EAAT2 and the Molecular Signature of Amyotrophic Lateral Sclerosis.
    Rosenblum LT; Trotti D
    Adv Neurobiol; 2017; 16():117-136. PubMed ID: 28828608
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Altered glutamatergic mechanisms and selective motor neuron degeneration in amyotrophic lateral sclerosis: possible role of glycine.
    Plaitakis A
    Adv Neurol; 1991; 56():319-26. PubMed ID: 1677233
    [No Abstract]   [Full Text] [Related]  

  • 45. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis.
    Van Den Bosch L; Van Damme P; Bogaert E; Robberecht W
    Biochim Biophys Acta; 2006; 1762(11-12):1068-82. PubMed ID: 16806844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Excitotoxins and amyotrophic lateral sclerosis.
    Munsat TL; Hollander D
    Therapie; 1990; 45(3):277-9. PubMed ID: 2194313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis.
    Lin CL; Bristol LA; Jin L; Dykes-Hoberg M; Crawford T; Clawson L; Rothstein JD
    Neuron; 1998 Mar; 20(3):589-602. PubMed ID: 9539131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular and cellular mechanism of glutamate receptors in relation to amyotrophic lateral sclerosis.
    Iwasaki Y; Ikeda K; Kinoshita M
    Curr Drug Targets CNS Neurol Disord; 2002 Oct; 1(5):511-8. PubMed ID: 12769603
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models.
    Ghadge GD; Slusher BS; Bodner A; Canto MD; Wozniak K; Thomas AG; Rojas C; Tsukamoto T; Majer P; Miller RJ; Monti AL; Roos RP
    Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9554-9. PubMed ID: 12876198
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects.
    Kanai Y; Hediger MA
    Pflugers Arch; 2004 Feb; 447(5):469-79. PubMed ID: 14530974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Revisiting Glutamate Excitotoxicity in Amyotrophic Lateral Sclerosis and Age-Related Neurodegeneration.
    Arnold FJ; Putka AF; Raychaudhuri U; Hsu S; Bedlack RS; Bennett CL; La Spada AR
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891774
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis.
    Foran E; Trotti D
    Antioxid Redox Signal; 2009 Jul; 11(7):1587-602. PubMed ID: 19413484
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Abnormal glutamate metabolism in amyotrophic lateral sclerosis.
    Plaitakis A; Caroscio JT
    Ann Neurol; 1987 Nov; 22(5):575-9. PubMed ID: 2892463
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of the N-methyl-d-aspartate receptors complex in amyotrophic lateral sclerosis.
    Spalloni A; Nutini M; Longone P
    Biochim Biophys Acta; 2013 Feb; 1832(2):312-22. PubMed ID: 23200922
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amyotrophic lateral sclerosis: Part 2. Etiopathogenesis.
    Tandan R; Bradley WG
    Ann Neurol; 1985 Oct; 18(4):419-31. PubMed ID: 2416263
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of neuroprotective effects of wedelolactone and gallic acid on aluminium-induced neurodegeneration: Relevance to sporadic amyotrophic lateral sclerosis.
    Maya S; Prakash T; Goli D
    Eur J Pharmacol; 2018 Sep; 835():41-51. PubMed ID: 30075221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Key Role of Astrocytes in Amyotrophic Lateral Sclerosis and Their Commitment to Glutamate Excitotoxicity.
    Provenzano F; Torazza C; Bonifacino T; Bonanno G; Milanese M
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895110
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies.
    Hollander D; Pradas J; Kaplan R; McLeod HL; Evans WE; Munsat TL
    Ann Neurol; 1994 Dec; 36(6):920-4. PubMed ID: 7998781
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amyotrophic lateral sclerosis-linked glutamate transporter mutant has impaired glutamate clearance capacity.
    Trotti D; Aoki M; Pasinelli P; Berger UV; Danbolt NC; Brown RH; Hediger MA
    J Biol Chem; 2001 Jan; 276(1):576-82. PubMed ID: 11031254
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glyoxal inactivates glutamate transporter-1 in cultured rat astrocytes.
    Kawaguchi M; Shibata N; Horiuchi S; Kobayashi M
    Neuropathology; 2005 Mar; 25(1):27-36. PubMed ID: 15822816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.